Position in GRFS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$223,989
-$163,208 QoQ
Shares Held
31,637
-34.5% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#73
of 164 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026ATLAS CAPITAL ADVISORS INC. holds $9,612,551 across 15 Drug Manufacturers - General names. GRFS ranks #8 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
3,869 | $4,640,595 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
7,901 | $998,212 | |
| 3 | MRK |
Merck & Co., Inc.
|
5,216 | $670,256 | |
| 4 | BIIB |
Biogen Inc.
|
2,930 | $633,055 | |
| 5 | BMY |
Bristol Myers Squibb Co
|
10,844 | $624,831 | |
| 6 | AZN |
Astrazeneca PLC
|
2,976 | $564,309 | |
| 7 | AMGN |
Amgen Inc
|
1,185 | $429,112 | |
| 8 | GRFS |
Grifols SA
This page
|
31,637 | $223,989 |
All Filings in GRFS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $223,989 | 31,637 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $387,197 | 48,279 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $451,408 | 48,279 | Shares | Sole | 2026-02-13 | |
| 2025-06-30 | $486,216 | 53,785 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $214,138 | 30,118 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $5,535 | 744 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $97,449 | 10,974 | Shares | Sole | 2024-11-05 | |
| No filing history on record for this holder in this stock. | ||||||